Table 5.
Outcomes after SRS per patient and CCM.
| Outcomes per 181 CCM | |
|---|---|
| Adverse radiation effect | 9 (5.0%) |
| New hemorrhage after SRS | |
| 1 | 18 (9.9%) |
| 2 | 1 (0.6%) |
| CCM volume at last FU | |
| Decreased | 77 (43.0%) |
| Stable | 99 (55.3%) |
| Increased | 3 (1.7%) |
| Unknown | 2 |
| Zabramski post SRS | |
| 1 | 15 (10.2%) |
| 2 | 87 (59.2%) |
| 3 | 34 (23.1%) |
| 4 | 11 (7.5%) |
| Unknown | 34 |
| Zabramski evolution before and after SRS | |
| Unchanged | 100 (68.5%) |
| PreSRS = 1 to post SRS 2 | 12 (8.2%) |
| PreSRS = 1 to post SRS 4 | 5 (3.4%) |
| PreSRS = 1 to post SRS 1 | 5 (3.4%) |
| PreSRS = 2 to post SRS 1 | 18 (12.3%) |
| PreSRS = 2 to post SRS 4 | 4 (2.7%) |
| PreSRS = 3 to post SRS 2 | 1 (0.6%) |
| PreSRS = 4 to post SRS 1 | 1 (0.6%) |
| Unknown | 35 |
| Outcomes for 170 patients | |
| Symptom evolution among patient | |
| Neurologic improvement | 69 (42.3%) |
| Neurologic stability | 81 (49.7%) |
| Neurological worsening | 13 (8.0%) |
| Missing data | 7 |
| New neurological deficit after SRS* | 27 (15.9%) |
| Transient | 15 (8.8%) |
| Permanent | 12 (7.1%) |
| Deficit due to ARE | 2 (2.1%) |
| Deficit due to a new hemorrhage of treated CCM | 11 (6.5%) |
| Deficit due to hemorrhage and ARE | 2 (2.1%) |
| New neurological deficit from other reason | 12 |
| Death | |
*Headaches and seizures were not taken into account for this classification.
ARE: Adverse radiation effect, CCM: cerebral cavernous malformations, FU: Follow-up, SRS: Stereotactic radiosurgery.